BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//LifeSci Events - ECPv6.15.11//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:LifeSci Events
X-ORIGINAL-URL:https://lifescievents.com
X-WR-CALDESC:Events for LifeSci Events
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20270314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20271107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260909T100000
DTEND;TZID=America/New_York:20260909T113000
DTSTAMP:20260815T172225
CREATED:20260720T124359Z
LAST-MODIFIED:20260814T142122Z
UID:3156-1788948000-1788953400@lifescievents.com
SUMMARY:Virtual KOL Event: GENFIT's Long-Term Revenue Opportunity and Strategic Developments in MASH Diagnostics
DESCRIPTION:Join GENFIT for a virtual key opinion leader (KOL) event featuring Vlad Ratziu\, MD\, PhD (Sorbonne University\, Pitié-Salpêtrière Hospital\, Institute for Cardiometabolism and Nutrition\, Paris). \nAs the MASLD/MASH landscape continues to evolve and new treatment options become available\, it is becoming increasingly clear that one of the next major challenges for the field will be identifying patients at risk earlier\, and at scale\, while ensuring they can be appropriately monitored over time. \nNASHnext® is a diagnostic test developed and commercialized by Labcorp as a laboratory developed test (LDT) under license from GENFIT. Based on GENFIT’s technology\, it uniquely captures both disease activity and fibrotic burden\, helping identify at-risk MASH patients and supporting more informed clinical decision-making. Medicare reimbursement under the Clinical Laboratory Fee Schedule became effective on August 10\, 2026\, marking an important milestone that may support broader adoption and future coverage by private insurers. \nGENFIT’s NIS4 and new generation NIS2+ technologies have been recognized by leading experts in the United States and Europe (NIMBLE and LITMUS). NIS2+ is included in the EASL-EASD-EASO Clinical Practice Guidelines. \nDr. Ratziu will discuss the clinical utility of the technology\, while company management will provide perspectives on market opportunities\, revenue potential\, and GENFIT’s in vitro diagnostic (IVD) development strategy. \nA live question-and-answer session will follow the formal presentations. Watch the webcast by clicking this link and logging in with the email address you used to register: https://lifescievents.com/event/yj29ot7/.
URL:https://lifescievents.com/event/yj29ot7/
LOCATION:Virtual\, Virtual
ATTACH;FMTTYPE=image/png:https://lifescievents.com/wp-content/uploads/2026/07/48ccdbd0-a39e-4df1-82a9-febe4ed519ce.png
END:VEVENT
END:VCALENDAR